Chinese state-backed institute providing testing, standards and certification for electric apparatus and equipment.
Chinese state-backed institute providing testing, standards and certification for electric apparatus and equipment.
Charges fees for testing, inspecting and certifying electrical and environmental performance, work manufacturers need before they can sell or supply some products. Income follows manufacturers' product launches and qualification cycles.
In one line: A China-based UL-style electrical certification body.
Moat: narrow (regulatory licence, installed base). State-linked certification role gives quasi-regulatory standing in its niche.
Headquarters: China · Employees: 3,218
Size China National Electric Apparatus Research Institute (688128.SS) is a China Industrials company (Miscellaneous Commercial Services) with a market value of $1.35B, the 1675th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥22.42 on 18 Nov 2026.
Performance Over six months the shares fell 17.0%, against -12.9% for the median peer and -20.0% for the China market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 7.6% over the last twelve months (peer median +4.9%); the operating margin is 10.6% (peer median 8.1%).
Valuation It trades at 14.7× forward earnings against a peer median of 23.3× (8th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -10 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.8 points above its cost of capital (8.2% WACC).
Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥5.21B | CN¥4.74B | CN¥4.51B | CN¥4.15B | CN¥3.78B |
| Revenue growth | — | +5% | +9% | +10% | — |
| Gross profit | CN¥1.82B | CN¥1.56B | CN¥1.41B | CN¥1.20B | CN¥1.02B |
| EBITDA | n/a | CN¥670M | CN¥558M | CN¥447M | CN¥379M |
| Net income | CN¥581M | CN¥534M | CN¥467M | CN¥410M | CN¥363M |
| Free cash flow | CN¥632M | CN¥926M | CN¥321M | CN¥166M | CN¥535M |
| Capital expenditure | CN¥333M | CN¥292M | CN¥214M | CN¥243M | CN¥182M |
| Total debt | CN¥419M | CN¥624M | CN¥367M | CN¥492M | CN¥572M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688128.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.7% | -2.3% | 7th highest of 21 |
| 6-month return | -17.0% | -12.9% | 10th lowest of 21 |
| Distance from 52-week high | -32.3% | -35.4% | 10th highest of 21 |
| Revenue growth (TTM) | +7.6% | +4.9% | 10th highest of 21 |
| Operating margin | 10.6% | 8.1% | 8th highest of 21 |
| Forward P/E | 14.7× | 23.3× | 8th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 3.2% | 8.8% | 5th least demanding of 17 |
| Growth delivered (Del g) | +13.5% | +11.1% | 8th highest of 17 |
| Hurdle (Req g minus delivered) | -10.4 pp | -3.0 pp | 5th least demanding of 17 |
| ROIC minus cost of capital | +7.8 pp | +0.3 pp | 4th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| China National Electric Apparatus Research Institute 688128.SS | China | $1.35B | -17% | +8% | 11% | 14.7× | 3.2% | +13.5% |
| China Security 600654.SS | China | $1.34B | -31% | -30% | -1% | n/a | 56.0% | +0.4% |
| SBS 2384.T | Japan | $1.35B | +26% | +17% | 5% | 13.9× | -4.7% | +13.8% |
| CRA International CRAI | United States | $1.35B | +46% | +13% | 10% | 23.3× | 6.6% | +8.1% |
| Changchun Up Optotech 002338.SZ | China | $1.34B | -41% | +22% | 2% | 43.1× | n/a | n/a |
| PharmaBlock Sciences (Nanjing) 300725.SZ | China | $1.36B | +5% | +11% | 11% | 37.5× | 24.2% | +14.1% |
| Derichebourg DBG.PA | France | $1.37B | -18% | -3% | 5% | 8.8× | 6.7% | +6.3% |
| TKC 9746.T | Japan | $1.31B | +22% | +5% | 20% | 19.1× | -10.1% | +5.7% |
| Clarivate CLVT | United States | $1.38B | -12% | -9% | 8% | 3.5× | 13.2% | +14.4% |
| Central Mine Planning & Design Institute CMPDI.NS | India | $1.38B | -22% | +10% | 33% | n/a | 4.5% | +18.7% |
| Shanghai MicroPort EP Medtech 688351.SS | China | $1.31B | -30% | +20% | 3% | 137.1× | 42.5% | +26.7% |
| Shanghai Medicilon 688202.SS | China | $1.39B | +8% | +42% | -2% | 85.1× | n/a | n/a |
| Shenzhen Ampron Technology 301413.SZ | China | $1.40B | -28% | +11% | 2% | 387.2× | n/a | n/a |
| Offcn Education Technology 002607.SZ | China | $1.40B | -40% | -2% | 13% | 34.7× | 15.7% | -27.6% |
| ICF International ICFI | United States | $1.40B | +14% | -5% | 8% | 10.4× | -2.5% | +4.4% |
| AFRY AFRY.ST | Sweden | $1.42B | +5% | -4% | 7% | 12.5× | -2.2% | +6.3% |
| Yangzhou Tinfulong 603406.SS | China | $1.42B | -29% | -4% | 12% | n/a | 6.1% | +10.6% |
| Shanghai Foreign Service 600662.SS | China | $1.42B | -14% | +1% | 2% | 13.2× | n/a | n/a |
| Suzhou Recodeal Interconnect System 688800.SS | China | $1.26B | -68% | +5% | 9% | 31.0× | 22.7% | +38.9% |
| Concord Biotech CONCORDBIO.NS | India | $1.26B | -2% | +4% | 28% | 33.9× | 44.4% | +11.6% |
| Moltiply MOL.MI | Italy | $1.45B | +12% | +20% | 16% | 14.0× | 10.9% | +21.0% |